Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Omentoplasty Medication

  • Author: Ashwin Pai, MBBS; Chief Editor: Kurt E Roberts, MD  more...
 
Updated: Aug 11, 2014
 

Medication Summary

The purpose of pharmacotherapy is to induce anesthesia.

Next

Anesthetic Agents

Class Summary

General anesthesia is preferred for this procedure. After anesthesia is induced, a 16-French or 18-French Ryle tube is passed and kept on continuous drainage. The patient is then catheterized with a 14-French Foley catheter to monitor intraoperative and postoperative urine output.

Propofol (Diprivan)

 

Propofol is a phenolic compound unrelated to other types of anticonvulsants. It has general anesthetic properties when administered intravenously. Propofol IV produces rapid hypnosis, usually within 40 seconds. The effects are reversed within 30 minutes, following the discontinuation of infusion. Propofol has also been shown to have anticonvulsant properties.

Etomidate (Amidate)

 

Etomidate is a nonbarbiturate imidazole compound with sedative properties. It is short acting and has a rapid onset of action; the duration of action is dose dependent (15-30 min). Its most useful feature as an induction agent is that it produces deep sedation while causing minimal cardiovascular effects.

The major application of etomidate is induction for endotracheal intubation, particularly in patients with, or at risk for, hemodynamic compromise. Etomidate has been shown to depress adrenal cortical function; however, this effect is not significant clinically during short-term administration. Since the drug is mixed in propylene glycol, continuous infusion is not recommended.

Thiopental

 

Thiopental is a short-acting barbiturate sedative-hypnotic with rapid onset and a duration of action of 5-20 minutes. Like methohexital, it is most commonly used as an induction agent for intubation. To use thiopental as a sedative, titrate in dosage increments of 25 mg (adjust to lower dose in children).

Previous
 
Contributor Information and Disclosures
Author

Ashwin Pai, MBBS MS (GenSurg), MRCS, Honorary Assistant Medical Officer, Department of Surgery, Kasturba Medical College, India

Disclosure: Nothing to disclose.

Chief Editor

Kurt E Roberts, MD Assistant Professor, Section of Surgical Gastroenterology, Department of Surgery, Director, Surgical Endoscopy, Associate Director, Surgical Skills and Simulation Center and Surgical Clerkship, Yale University School of Medicine

Kurt E Roberts, MD is a member of the following medical societies: American College of Surgeons, Society of American Gastrointestinal and Endoscopic Surgeons, Society of Laparoendoscopic Surgeons

Disclosure: Nothing to disclose.

References
  1. Hoshino S, Nakayama K, Igari T, Honda K. Long-term results of omental transplantation for chronic occlusive arterial diseases. Int Surg. 1983 Jan-Mar. 68(1):47-50. [Medline].

  2. Casten DF, Alday ES. Omental transfer for revascularization of the extremities. Surg Gynecol Obstet. 1971 Feb. 132(2):301-4. [Medline].

  3. Sasajima T, Kubo Y, Izumi Y, Inaba M, Goh K. Plantar or dorsalis pedis artery bypass in Buerger's disease. Ann Vasc Surg. 1994 May. 8(3):248-57. [Medline].

  4. Stricht VJ, Goldstein M, Flamand JP, Belenger J. Evolution nad prognosis of thromboangitis obliterans. J Cardiovasc surg (Torino). 1973. 14:9-16.

  5. Kunlin J, Lengua F, Testart J, Pajot A. Thromboangiosis or thromboangeitis treated by adrenalectomy and sympathectomy from 1942 to 1962. A follow-up study of 110 cases. J Cardiovasc Surg (Torino). 1973 Jan-Feb. 14(1):21-7. [Medline].

  6. Komori K, Kawasaki K, Okazaki J, Eguchi D, Mawatari K, Okadome K. Thoracoscopic sympathectomy for Buerger's disease of the upper extremities. J Vasc Surg. 1995 Sep. 22(3):344-6. [Medline].

  7. Nakajima N. The change in concept and surgical treatment on Buerger's disease--personal experience and review. Int J Cardiol. 1998 Oct 1. 66 Suppl 1:S273-80; discussion S281. [Medline].

  8. Goldsmith HS, Griffith AL, Catsimpoolas N. Increased vascular perfusion after administration of an omental lipid fraction. Surg Gynecol Obstet. 1986 Jun. 162(6):579-83. [Medline].

  9. Goldsmith HS, Griffith AL, Kupferman A, Catsimpoolas N. Lipid angiogenic factor from omentum. JAMA. 1984 Oct 19. 252(15):2034-6. [Medline].

  10. Bronzetti G, Galli A, Della Croce C. Antimutagenic effects of chlorophyllin. Basic Life Sci. 1990. 52:463-8. [Medline].

  11. Agarwal VK, Bajaj S. Salvage of end stage extremity by omentopexy in Buerger’s disease. Indian Journal of Thoracic and cardiovascular surgery. 1987. 5:12-17.

  12. Subodh S, Mohan JC, Malik VK. Omentopexy in limb revascularisation in Buerger's disease. Indian Heart J. 1994 Nov-Dec. 46(6):355-7. [Medline].

  13. Borham MM. Comparison between omentoplasty and partial cystectomy and drainage (PCD) techenques in surgical management of hydatid cysts liver in endemic area (Yemen). J Egypt Soc Parasitol. 2014 Apr. 44(1):145-50. [Medline].

  14. Killeen S, Mannion M, Devaney A, Winter DC. Omentoplasty to assist perineal defect closure following laparoscopic abdominoperineal resection. Colorectal Dis. 2013 Oct. 15(10):e623-6. [Medline].

  15. Boiskin I, Karna A, Demos TC, Blakeman B. Herniation of the transverse colon: an unusual complication of pedicled omentoplasty. Can Assoc Radiol J. 1995 Jun. 46(3):223-5. [Medline].

 
Previous
Next
 
Omentoplasty. Omentum being mobilized.
Omentoplasty. Omentum being mobilized to reach below knee.
Omentoplasty. Skin incisions made on limb for subcutaneous tunneling of omentum.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.